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An innovative magnetic delivery nanomaterial for triggered cancer 
therapy showing active control over drug release by using 
alternative magnetic field is proposed. In vitro and in living cells 
release of doxorubicin (DOX) were investigated and showed a 
massive DOX release upon alternative magnetic field without 
temperature elevation of the medium. 
      During the last decade, nanotechnologies for anticancer 
drug delivery
1
 have been extensively explored, hoping to 
improve local efficacy and to reduce side effects of 
chemotherapy. In an ideal targeted drug delivery system, 
nanomaterials would be directed to the tumor tissue and 
selectively release therapeutic molecules.  
       Molecularly imprinted polymers
2
 (MIPs), which possess 
selective affinity and sustained release behavior toward 
specific biomolecules have found applications in biosensing
3
, 
drug delivery
4
, bioseparation
5
 as well as diagnostics and 
therapeutics
6
. The biomolecules served as templates during 
the polymerization of the functional monomer to get the MIP. 
The advantage in drug delivery of such a system is the 
possibility to regulate drug release by increasing the residence 
time of the therapeutic agent within the polymeric matrix, by 
means of either covalent or non-covalent interactions in 
specific binding sites. The release of the drug doesn’t depend 
on the swelling degree of the polymer unlike strategy involving 
a polymer shell.  
       Magnetic nanoparticles have attracted considerable 
attention for magnetic targeting
7
 and magnetic hyperthermia 
applications
8
 owing to their ability to generate heat when 
exposed to an alternative magnetic field (AMF) without 
penetration depth limit. However, heat therapy with magnetic 
hyperthermia needs a high accumulation of nanoparticles to 
provide macroscopic therapeutic heating, quite unrealistic 
with systemic delivery. As a consequence, new strategies were 
recently envisaged to trigger drug delivery.
9,10
 Temperature-
responsive carriers like mesoporous silica NPs coated with a 
thermosensitive polymer
11
, polymersomes
12
, liposomes
13
 or 
microgels
14
 exhibit an increase of permeability above a defined 
transition temperature which induces subsequent release of 
the drugs. Another way to induce the drug delivery is to use 
hyperthermia to break bonds between magnetic nanoparticles 
and the drug
15
. That is the case of a recent study where ligands 
linked to magnetic nanoparticles took benefits from local 
heating of nanoparticle’s surface to release a fluorophore on 
demand
16
. The weak interactions existing in supramolecular 
magnetic nanoparticles can also be broken under AMF like J. 
Cheon and co-workers proposed
17
. This approach is very 
interesting because it can be performed without macroscopic 
temperature elevation
18
.  
      In this study we propose to destabilize the weak 
interactions existing between the MIP and the drug to trigger 
the drug release in athermal conditions under AMF. We 
designed a new magnetic doxorubicin delivery system 
(Fe2O3@DOX-MIP) by growing molecularly imprinted polymers 
from individual iron oxide nanoparticles surface via an acrylic 
acid monomer (AA) used as polymerization initiator anchored 
on the surface of Fe2O3 nanoparticles and doxorobucin as 
template
19
. The DOX release of such functional Fe2O3@DOX-
MIP NPs was investigated in vitro and in living cells under AMF 
excitation.  
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Scheme 1. Two-step synthesis of Fe2O3@DOX-MIP via a 
subsequent grafting of an acrylic acid compound and the 
growth of the polymer at 70°C. AMF induces DOX release. 
 
We prepared Fe2O3@DOX-MIP NPs according to Scheme 1. 
The -Fe2O3 NPs (maghemite) were first synthesized through a 
coprecipitation method, followed by a size sorting process 
through salt destabilization to get the biggest NPs which are 
more efficient for magnetic hyperthermia
20
. 
      TEM analysis shows particles with an average particle 
diameter (d0) of 11 nm and a polydispersity (of 0.31 (Fig. 
S1a, ESI†). To stabilize and functionalize the Fe2O3 NPs, an 
acrylic acid function was anchored by complexation with 
unsaturated iron ions at the nanoparticle surface. Then, the 
polymerization could proceed, mixing Fe2O3-AA nanoparticles 
with acrylamide as the functional monomer, ethylene 
glycoldimethacrylate (EGDMA) as the crosslinking agent, 
azo(bis)isobutyronitrile (AIBN) as the polymerization initiator 
and doxorubicin (DOX) as the template molecule in ethanol. 
The deoxygenated mixture was heated for 16h. The final 
product, consisting of nanoparticles coated by a molecularly 
imprinted polymer (Fe2O3@DOX-MIP), was dialyzed during 24 
hours, washed several times by magnetic separation and 
finally dispersed in water. A reference non-imprinted polymer 
sample (Fe2O3@NIP) was prepared using the same procedure, 
but without addition of the template (DOX molecules). It is 
noteworthy that the polymer layer for Fe2O3@DOX-MIP 
nanoparticles (Fig. S1b, ESI†) is too thin to appear on the TEM 
images, however no morphological change or aggregation is 
observed due to polymerization process. 
      The surface chemistry of the Fe2O3@DOX-MIP was 
assessed by Fourier transform infrared (FT-IR; Fig. S2, ESI†). 
The Fe-O stretching peak at ∼586 cm-1 was observed for the 
two samples, indicating that the composition of Fe2O3 was not 
changed after polymer coating. The band observed for the 
Fe2O3 particles at 1385 cm
-1
, characteristic of the nitrate ion 
with D3h symmetry (ν3 mode), is not visible after 
polymerization indicating the surface modification of the 
particles. The vibration band at 1728 cm
-1
 (C=O stretching) 
appears when magnetic nanoparticles were covered with MIP 
that contains a large number of C=O groups in poly-
(acrylamide) units confirming the successful growth of 
polymer.  
      Thermogravimetric analysis (TGA) showed that the amount 
of MIP on Fe2O3@DOX-MIP was about 70% of the total particle 
weight, as determined from the significant mass change 
between 270 and 400°C owing to decomposition of MIP (Fig.  
S3, ESI†). 
      The Fe2O3 NPs were found to be covered with MIP after 
polymerization, as observed by the increase in size (from 31 to 
57 nm) using dynamic light scattering (DLS – Fig. S4, ESI†). DLS 
and zeta potential were measured for both Fe2O3 and 
Fe2O3@DOX-MIP NPs versus pH (Fig. S5a and S5b, ESI†). The 
hydrodynamic diameter of Fe2O3@DOX-MIP particles is 
constant on the whole pH range according to their constant 
zeta potential (-27 mV). As the poly(acrylamide) is non pH 
sensitive, this result is in agreement with the effective surface 
modification of the Fe2O3 NPs with the polymer coating.   
      Kinetic adsorption tests (Fig. S6, ESI†) onto the 
Fe2O3@DOX-MIP after DOX extraction (named Fe2O3@MIP) 
and Fe2O3@ NIP were performed by measuring the adsorption 
of DOX at regular intervals from 5 to 120 min with the same 
initial concentration of DOX (400 µM). The adsorption capacity 
(Q) of DOX onto the Fe2O3@MIP has a fast adsorption profile 
within 20 min, and then slows down gradually. After 20 min, 
the adsorption has almost reached equilibrium. Compared to 
other surface imprinting technologies for DOX, the adsorption 
equilibrium time of the Fe2O3@MIP is similar
18
. 
      Isothermal adsorption experiments were carried out 
through varying the concentrations of DOX from 20 to 400 µM, 
with a mixing time of 3 hours (Fig. 1). It was shown that the Q 
of DOX onto the Fe2O3@MIP and Fe2O3@NIP came to 
equilibrium over 200 µM. The results suggest that the 
recognition sites on the surface of the Fe2O3@MIP have better 
chemical and steric matching with the DOX than Fe2O3@NIP 
indicating a non-specific adsorption as the dominant effect and 
a lower binding affinity of Fe2O3@NIP. The dissociation 
constant Kd and the maximum binding number (Qmax) were 
calculated from the Scatchard equation for the prepared 
polymers (Fig. S7, ESI†). The respective Kd and Qmax values are 
35.6 µmol g
-1
 and 3.4µM for the Fe2O3@DOX-MIP and 12.5 
µmol g
-1
 and 100µM for the Fe2O3@DOX-NIP. The difference in 
DOX binding affinity to the MIP and NIP clearly indicated the 
role of the imprinting process in the formation of specific 
binding sites.   
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Fig. 1 Adsorption isotherms of Fe2O3@MIP (black) and 
Fe2O3@NIP (red) toward Doxorubicin. Adsorption conditions: V 
= 5 mL, mMIPs = mNIPs = 20mg, T = 25 °C, t = 3h . 
 
      Fe2O3 and Fe2O3@DOX-MIP NPs exhibit the same 
superparamagnetic behavior (Fig. S8, ESI†). More interestingly, 
the heating capacity also called the Specific Loss Power (SLP) of 
Fe2O3 and Fe2O3@DOX-MIP nanoparticles was measured at 
335 kHz and 9mT magnetic field. The uncoated NPs exhibit a 
SLP of 97 W.g
-1
 in good agreement with theoretical and 
experimental expectations
20
. For the Fe2O3@DOX-MIP, a SLP 
of 67 W.g
-1
 is obtained with a temperature elevation rate of 
0.33°C.s
-1
. The SLP decrease may be explained by the 
appearance of some aggregates after polymerization as 
observed by DLS. However, the Fe2O3@DOX-MIP nanoparticles 
still have an interesting heating capacity if they are submitted 
to an alternative magnetic field.  
      To investigate the potential application of Fe2O3@DOX-MIP 
for drug delivery, in vitro DOX release studies were monitored 
in various conditions: in a water bath at human body 
temperature (37°C) and under AMF (five AMF pulses of 2 
minutes with a 30s interval, 335 kHz, 9mT) at 37°C (Fig. 2A and 
2C).  In order to determine the concentration of the DOX binds 
to the MIP, DOX molecules were extracted in a solvent 
(ethanol/acetic acid 9:1v/v). Extraction of the template is 
commonly done with a solvent that promotes the disruption of 
interactions between the polymer and the template while 
maintaining the structure of the three-dimensional polymer 
network
21
. The supernatant was then collected by magnetic 
separation and analyzed by UV/Vis spectroscopy 1, 2, 3, 4, 6 
and 8h after treatment; the materials released 12 µM of DOX 
after 8h (Fig. 2A). The amount of DOX extracted in acetic acid 
is used as reference for the calculation of the percentage of 
drug release (Fig. 2C). Then, samples (Fe2O3@DOX-MIP NPs, 2 
mL, [Fe]=50mM) were periodically placed under AMF at the 
same time points. Fe2O3@DOX-MIP NPs submitted to AMF 
released 7.5 µM of DOX after 8h at 37°C (Figure 2A) whereas a 
sample left for 8h at 37°C did not show any significant DOX 
release (15%, Fig. 2B). Therefore the cumulative drug release 
reaches 60% under AMF. More interestingly for each time 
point, the drug release is significantly higher when the 
nanoparticles are submitted to an AMF. To evaluate the 
imprinting process role in the DOX release under AMF, 
Fe2O3@NIP NPs were incubated with DOX (C = 40µM, see 
supporting information) during 4h, dialyzed during 24h and 
washed several times by magnetic separation and finally 
dispersed in water. The final product (Fe2O3@NIP-DOX, 2mL, 
[Fe]=50mM, CDOX= 12 µM) was submitted to the same AMF 
excitation than the Fe2O3@DOX-MIP NPs. A sample left for 8h 
at 37°C (Figures 2B and 2D) showed a high DOX concentration 
release (9µM, 73%) and under AMF the same material showed 
the complete release of the DOX after 8h (11,8 µM, 98%). A 
burst effect is observed when the DOX is just physically 
retained in the unprinted polymer shell around the particles. 
The slight effect observed upon AMF excitation is probably due 
to a more rapid diffusion of DOX molecules with the 
temperature elevation in the polymer matrix. These results 
taking together highlight the importance of the drug 
interactions with the polymer in the imprinting process to slow 
the release of the drug from the polymer network.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Cumulative DOX release in µmol/L and in percent versus 
time of Fe2O3@DOX-MIP (A) and (B) and Fe2O3@NIP-DOX 
nanoparticles (C) and (D) ([Fe]=50 mM) (a) after acid 
treatment, (b) at 37°C without magnetic field and (c) under 
AMF (335 kHz, 9mT). 
 
    To prove the universality of the imprinted method to other 
molecules, the same protocol has been carried out with 
fluorescein and rhodamine (Fig. S9, ESI†). Both imprinted 
particles exhibit a significant template release after AMF 
treatment compared to the sample without AMF (respectively 
11.8 and 13.6 µM versus 1.9 and 2.3µM). 
     To show the crucial role of the magnetic core in the drug 
release process Fe2O3 NPs were dissolved in HCl and after 
separation of the polymer from the acidic solution by 
ultracentrifugation, in vitro DOX release studies were 
monitored at 37°C under AMF. After 8h, the DOX release 
concentration is insignificant (1.5µM, Fig. S10, ESI†) confirming 
the importance of the magnetic core in the drug delivery 
system. As nanoparticles preferentially accumulate at the 
tumour site thanks to the Enhanced Permeability and 
Retention effect (EPR effect), using Fe2O3@DOX-MIP as drug 
delivery system could be useful in AMF-induced drug delivery 
applications.  
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      To evaluate the temperature effect on the drug-release 
profile, Fe2O3@DOX-MIP nanoparticles were heated at 
different temperatures (water bath) during 4 hours and 
supernatants were analyzed after magnetic separation (Fig. 
S11, ESI†).  The DOX concentration released after a bulk 
heating during 4h at 37°C is of the order of 1.2 µM which is 
three times lower than the amount of DOX released after 4 
hours with AMF pulse at each time point (5.6 µM, Fig. 1A, ESI†) 
at the same temperature. The maximum of DOX release 
reached under AMF (7.5 µM) is obtained for a temperature of 
60°C whereas macroscopic temperature elevation measured 
during AMF experiments is only of 3°C (Fig. S12, ESI†). 
Therefore, we can conclude that the effect of AMF is due to a 
high temperature gradient from the nanoparticle surface, this 
gradient is restricted to the environment close to the 
periphery of the nanoparticle, thus leading to localized 
heating. The effect of this localized heating on the drug release 
may be explained by the destabilization of the weak 
interactions (hydrogen bonds) existing between the DOX and 
the MIP. 
      DOX release was then tested in cancer cells, with a view to 
future therapeutic application. Fe2O3@DOX-MIP nanoparticles 
were very efficiently captured by cancer cells (PC-3), with an 
iron load per cell of 10 pg, when incubation (2-hours) was 
performed at [Fe]=2 mM (see also the uptake curve in Fig. 
S13). This [Fe]=2mM concentration corresponds to a maximal 
DOX release on µmolar range (Fig. 2A). DOX was clearly 
associated to the tumor cells on confocal microscopy images 
(Fig. 3A), and cross-sectional images of the cells (Fig. 3B and 
Fig. S14, ESI†) demonstrate unambiguously its intracellular 
localization, sequestered inside intracellular endosome-like 
compartments. These Fe2O3@DOX-MIP nanoparticles 
internalization did not induce cancer cell death (Fig. 3C), 
demonstrating that when bonded to the MIP (and thus the 
nanoparticles), DOX is inactive. By contrast, after AMF 
application (at 700 kHz, 25 mT), cancer cell viability was 
affected, with cell viability reduced to 60% after 1h30 
treatment (Fig. 3C). It is very important to emphasize here that 
this AMF-induced cancer cell death was achieved in athermal 
conditions. Indeed, during the AMF exposure, the cell medium 
was maintaining at a 37°C temperature (See Fig. S15, ESI† for 
the temperature monitoring during treatment). This is in 
agreement with the control experiment where cells loaded 
with the same amount of iron (10 pg per cell) but without DOX 
(incubation with Fe2O3@citrate nanoparticles, with same 
magnetic core as Fe2O3@DOX-MIP nanoparticles) didn’t suffer 
any mortality.  Also worth noticing, the same levels of cell 
deaths were found when free DOX was incubated with the 
cancer cells for 2 hours at concentration in the range 0.5-2 µM 
(Fig. 3D), corresponding remarkably to the concentration 
which could be AMF released by the Fe2O3@DOX-MIP 
incubated with the cells. Taken together, these cellular 
experiments support the DOX release under AMF application 
evidenced in solution, and demonstrate the possibility of 
initiating a chemotherapeutic treatment via an athermal 
magnetic hyperthermia strategy. This remote magnetic 
activation of doxorubicin is particularly promising to limit the 
adverse effects of chemotherapy on bystander tissues.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 (A,B): Cancer cells (PC-3) internalization of the 
Fe2O3@DOX-MIP nanoparticles (2-hours incubation at [Fe]=2 
mM). DOX is detected in the green channel (excitation at 488 
nm, emission at 561 nm). Nuclei and cell membranes are 
stained by DAPI (A) in blue and PKH26 (A,B) in red, 
respectively. Z reconstructions (B) identify DOX inside the cells. 
(C): Viability of cancer cells labelled with Fe2O3@DOX-MIP 
after exposure to the alternative magnetic field (AMF at 700 
kHz, 25 mT) for 0min (No AMF), 30min, 1h30, and 2h30 
compared to the control experiment (cancer cells labelled with 
Fe2O3 nanoparticles, at the same cellular iron dose, and 
exposed to the same conditions of AMF). The overall 
temperature during treatment was 37.,5 °C for both 
conditions. (D) Treatment of the cancer cells with free 
doxorubicin (DOX) incubated for 2 hours from 0.5 to 50 µM. 
Cell viability (normalized by control cells) was measured 24 
hours after the incubation, in the exact same conditions as the 
ones used for Fe2O3@DOX-MIP after AMF treatment. 
      In summary, we reported the synthesis of an innovative 
magnetic delivery nanoplatform for triggered cancer therapy 
showing active control over drug release by using local effect 
of hyperthermia. Our material, wich combines the controlled 
drug release ability of non thermosensitive Molecularly 
Imprinted Polymers (MIP) with magnetic properties of iron 
oxide, allows the control release of doxorubicin. Upon AMF 
exposure, the hydrogen bonds between the MIP and the DOX 
are broken and the molecule is released without any 
significant heating of the medium. This strategy is efficient 
both in vitro and in living cells. These nanomaterials offer great 
promise for the doxorubicin release under magnetic field and 
moreover we think that this approach will be easily expanded 
to other polymers, targeting molecules or drugs. The use of 
Magnetic Molecularly Imprinted Polymers for drug delivery 
under alternative magnetic field (AMF) is a major advance in 
the development of multifunctional targeted drug delivery 
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nanotechnologies and may become important theranostic 
tools in nanomedicine. 
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